ENTRY       D12334            Mixture   Drug
NAME        Nivolumab and relatlimab;
            Nivolumab and relatlimab-rmbw;
            Opdualag (TN)
PRODUCT     OPDUALAG (E.R. Squibb & Sons)
COMPONENT   Nivolumab [DR:D10316], Relatlimab [DR:D11350]
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      ATC code: L01XY03
            Product: D12334<US>
EFFICACY    Antineoplastic, Immune checkpoint inhibitor
  DISEASE   Melanoma [DS:H00038]
  TYPE      Monoclonal antibody, combination
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XY Combinations of antineoplastic agents
                 L01XY03 Nivolumab and relatlimab
                  D12334  Nivolumab and relatlimab &lt;US&gt;
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D12334  Nivolumab and relatlimab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D12334  Nivolumab and relatlimab
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12334
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12334
///
